Payment overview · 2025
General Payments
$580.50
32 reported records · 12 companies
Healthcare provider profile · identity verified
Asmik Mkrtychyan, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · DETROIT, MI · NPI 1295024743
Verified facts
What the public records show
CMS Open Payments records show Asmik Mkrtychyan, FNP received $580.50 in general payments during 2025 across 32 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $144.41 | 24.9% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $122.44 | 21.1% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.19 | 12.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.98 | 10.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.27 | 6.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.03 | 5.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.99 | 4.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.10 | 3.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.79 | 3.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.65 | 2.7% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $14.52 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.13 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $580.50 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $144.41 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $87.81 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.19 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $72.19 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $61.98 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.27 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 255 | 143 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 220 | 111 |
| Omeprazole | Omeprazole | 167 | 89 |
| Lisinopril | Lisinopril | 154 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 84 |
| Gabapentin | Gabapentin | 150 | 69 |
| Metformin Hcl | Metformin Hcl | 133 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 59 |
| Ibuprofen | Ibuprofen | 106 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 103 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 52 |
| Alendronate Sodium | Alendronate Sodium | 87 | 42 |
| Trazodone Hcl | Trazodone Hcl | 87 | 47 |
| Simvastatin | Simvastatin | 83 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 33 |
| Farxiga | Dapagliflozin Propanediol | 77 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 39 |
| Montelukast Sodium | Montelukast Sodium | 72 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 34 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 65 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 33 |
| Fenofibrate | Fenofibrate | 61 | 22 |
| Jardiance | Empagliflozin | 58 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 57 | 26 |
| Ozempic | Semaglutide | 56 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 29 |
| Trulicity | Dulaglutide | 53 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 29 |
| Buspirone Hcl | Buspirone Hcl | 50 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | 20 |
| Tramadol Hcl | Tramadol Hcl | 40 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 23 |
| Losartan Potassium | Losartan Potassium | 38 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 19 |
| Sertraline Hcl | Sertraline Hcl | 35 | 19 |
| Eliquis | Apixaban | 33 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 33 | 21 |
| Ezetimibe | Ezetimibe | 32 | 17 |
| Azithromycin | Azithromycin | 31 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | 17 |
| Furosemide | Furosemide | 31 | 18 |
| Topiramate | Topiramate | 30 | 13 |
| Mirtazapine | Mirtazapine | 29 | 16 |
| Alprazolam | Alprazolam | 28 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | 13 |
| Allopurinol | Allopurinol | 27 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 15 |
| Naproxen | Naproxen | 27 | 12 |
| Prednisone | Prednisone | 27 | 23 |
| Dutasteride | Dutasteride | 26 | 11 |
| Carvedilol | Carvedilol | 25 | 16 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 15 |
| Diazepam | Diazepam | 25 | 18 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | 11 |
| Pregabalin | Pregabalin | 24 | 12 |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | 13 |
| Meclizine Hcl | Meclizine Hcl | 23 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | 11 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 21 | suppressed |
| Famotidine | Famotidine | 20 | 14 |
| Finasteride | Finasteride | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | 12 |
| Meloxicam | Meloxicam | 19 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | 11 |
| Ammonium Lactate | Ammonium Lactate | 18 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $580.50 · 32 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, Auvelity, CAPLYTA, Cologuard Collection Kit, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, SUBLOCADE, TRELEGY ELLIPTA, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error